Anixa Biosciences (NASDAQ:ANIX) Receives “Buy” Rating from D. Boral Capital

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $10.00 target price on the stock. D. Boral Capital’s target price suggests a potential upside of 217.46% from the stock’s previous close.

ANIX has been the subject of a number of other reports. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a research note on Tuesday. Maxim Group started coverage on Anixa Biosciences in a research report on Friday, March 21st. They set a “buy” rating and a $10.00 price objective for the company.

Anixa Biosciences Stock Down 1.6 %

Shares of ANIX stock opened at $3.15 on Wednesday. The company has a market cap of $101.42 million, a P/E ratio of -8.08 and a beta of 0.86. The business has a 50 day moving average of $2.94 and a two-hundred day moving average of $3.00. Anixa Biosciences has a 52 week low of $2.07 and a 52 week high of $4.20.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.10) EPS for the quarter, hitting analysts’ consensus estimates of ($0.10). Analysts expect that Anixa Biosciences will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Lewis H. Titterton, Jr. acquired 10,000 shares of the stock in a transaction that occurred on Friday, January 17th. The shares were acquired at an average price of $2.57 per share, for a total transaction of $25,700.00. Following the completion of the purchase, the director now directly owns 922,334 shares of the company’s stock, valued at $2,370,398.38. The trade was a 1.10 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Amit Kumar bought 43,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were purchased at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the acquisition, the chief executive officer now owns 559,925 shares of the company’s stock, valued at $1,248,632.75. This represents a 8.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 75,289 shares of company stock valued at $177,021 over the last 90 days. 25.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Anixa Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC acquired a new stake in shares of Anixa Biosciences in the fourth quarter valued at $26,000. Virtu Financial LLC acquired a new position in Anixa Biosciences during the third quarter worth about $34,000. Renaissance Technologies LLC raised its position in Anixa Biosciences by 36.5% in the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock worth $34,000 after acquiring an additional 3,900 shares in the last quarter. Prosperity Wealth Management Inc. acquired a new stake in Anixa Biosciences in the 4th quarter valued at about $54,000. Finally, Jane Street Group LLC bought a new position in shares of Anixa Biosciences during the 4th quarter valued at about $67,000. 29.13% of the stock is owned by institutional investors.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.